SAN ANTONIO, TX, JULY 15, 2009 11:00 A.M. (CST).

America Stem Cell, Inc. (ASC) announced today that the company has been awarded $2.5 million
from the State of Texas Emerging Technology Fund (“ETF”)
This investment will enable ASC to accelerate the development of its breakthrough enzyme
technology to enhance the homing and engraftment of cord blood stem cells, and achieve
improved clinical outcomes for cancer patients receiving these stem cell transplants. ASC’s
enzyme treatment could potentially transform cord blood stem cell engraftment, accelerate
patients’ immune system and platelet recovery, reduce opportunistic infections and improve
cord blood stem cell transplant patient survival and quality of life. This enzyme treatment will
enable the tens of thousands of adult cancer patients in the U.S. to be treated quickly with
umbilical cord blood, versus enduring what is often a long and futile wait for matching
marrow or peripheral blood stem cells, during which time many patients die needlessly.

“Texas is the best state in the nation to live, work and do business, and the ETF is helping
supercharge our technology environment by bringing Texans’ good ideas and hard work to
the marketplace,” Texas Gov. Rick Perry said. “This investment demonstrates our
commitment to improving the lives of cancer patients by developing innovative cord blood
stem cell technology, while protecting the unborn from exploitation.”
“There are stringent criteria for emerging technology companies to win an ETF award. ASC
had many strengths in their application including an innovative enzyme technology which
has the potential to address unmet cancer patient needs, a strong worldwide patent position
and an experienced research and management team,” Jim Poage, President and CEO of
SATAI and the STRCIC said. “ASC is poised to provide significant contributions to the
growth of the biotechnology industry in San Antonio”.
“We are very grateful to the various ETF committees who, after extensive and thorough due
diligence, have decided to make this important award to America Stem Cell. We will utilize
these funds to effectively accelerate our development forward to start our Phase I/II clinical
trials at MD Anderson, position ourselves to achieve additional funding and drive towards
achieving human proof of concept and worldwide market launch of our breakthrough
enzyme technology,” Lynnet Koh, Chief Executive Officer/Founder of America Stem Cell
said. “We believe that we are well positioned to be the world market leader in stem cell
homing and engraftment technologies and we are proud to be part of Texas’ achievements
in the fields of stem cell transplantation and biotechnology”.

About America Stem Cell, Inc. (ASC)
ASC is a privately held biotechnology company dedicated to the development and
commercialization of enabling technologies to enhance and expand the therapeutic potential
of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed
to improve the homing and engraftment of stem cells to target organs and increase their
therapeutic potential for cancer patients. Additionally, these platforms have the potential to
enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors,
autoimmune diseases, and ischemic diseases including myocardial infarction and stroke.
ASC has strategic partnerships with medical research institutions including the University of
Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation,
University of California, the Burnham Institute, Indiana University, Rush Presbyterian and
VidaCord Technologia Biomedica. For additional information, please contact Lynnet Koh at